Current Report Filing (8-k)
December 03 2019 - 4:49PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 26, 2019
CANFIELD
MEDICAL SUPPLY, INC.
|
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Colorado
|
(State
or Other Jurisdiction of Incorporation)
|
|
|
|
|
|
|
000-55114
|
|
34-1720075
|
(Commission File
Number)
|
|
(IRS Employer Identification
No.)
|
|
|
|
|
|
|
4120
Boardman-Canfield Road
Canfield,
Ohio 44406
|
(Address
of Principal Executive Offices)
|
|
|
|
(330)
533-1914
|
(Registrant's
Telephone Number, Including Area Code)
|
|
|
|
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Effective
after trading hours on November 26, 2019, Canfield Medical Supply, Inc. (the “Company”) granted options to an officer
and directors as follows:
Name
|
Title
|
Amount
|
John
Matthias Lepo
|
Interim
Chief Executive Officer, Chief Financial Officer and Director
|
120,000
|
Michael
Long
|
Director
|
45,000
|
Amy
Atkinson
|
Director
|
45,000
|
The
options (i) are exercisable as of the date of grant, (ii) have a strike price of $0.55 per share, which was the reported closing
bid price per share of the Company’s common stock on the date of grant, and (iii) expire 60 months from the date of grant.
A
form of the option agreement is attached as Exhibit 10.1 to this report and the foregoing description of the options is qualified
in its entirety by reference thereto.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
December 3, 2019
CANFIELD
MEDICAL PRODUCTS, INC.
/s/ John Matthias Lepo
|
|
|
By:
John Matthias Lepo
|
|
|
Interim
Chief Executive Office and Chief Financial Officer
|
|
|
|
|
|
|
|
|